Randomized Trial of Tacrolimus Monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (The TICTAC Trial)

Journal of Heart and Lung Transplantation

Volumn 26, Issue 10, 2007, Pages 992-997

  Baran, David A ^a   Zucker, Mark J ^a   Arroyo, Luis H ^a   Alwarshetty, Mamata M ^a   Ramirez, Maria R ^a   Prendergast, Thomas W ^a   Goldstein, Daniel J ^a   Camacho, Margarita ^a   Gass, Alan L ^b   Carr, Candace ^a   Cohen, Marc ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

AGED; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART TRANSPLANTATION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TREATMENT OUTCOME;

EID: 34848890583     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.07.022     Document Type: Article

References (20)

1. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24 (2005) 119-130
2. Baran D.A., Segura L., Kushwaha S., et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant 20 (2001) 59-70
3. Lubitz S.A., Baran D.A., Alwarshetty M.M., et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 699-706
4. Jain A., Reyes J., Kashyap R., et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression?. Long-term follow-up of the first 1000 patients. Ann Surg 230 (1999) 441-448 discussion 448-9
5. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 (1990) 587-593
6. Winters G.L., Marboe C.C., and Billingham M.E. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 17 (1998) 754-760
7. Mehra M.R., Ventura H.O., Chambers R., et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 26 (1995) 1537-1544
8. Yamani M.H., Yousufuddin M., Starling R.C., et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy?. J Heart Lung Transplant 23 (2004) 272-276
9. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
10. Gonzalez-Stawinski G.V., Cook D.J., Chang A.S., et al. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. J Heart Lung Transplant 25 (2006) 613-618
11. Mehra M.R., Uber P.A., Scott R.L., et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 74 (2002) 1568-1573
12. Pamboukian S.V., Heroux A., Bartlett L., et al. Is outcome after heart transplantation influenced by ethnicity?. A comparison of African Americans versus Caucasians. J Heart Lung Transplant 20 (2001) 238
13. Zucker M.J., Baran D.A., Arroyo L.H., et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. Transplant Proc 37 (2005) 2231-2239
14. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525
15. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 (2006) 398-405
16. Tu W., Potena L., Stepick-Biek P., et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114 (2006) 1608-1615
17. Lietz K., John R., Burke E., et al. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 112 (2005) 2468-2476
18. Mehra M.R., Benza R., Deng M.C., Russell S., and Webber S. Surrogate markers for late cardiac allograft survival. Am J Transplant 4 (2004) 1184-1191
19. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 (2004) S187-S193
20. Vasilescu E.R., Ho E.K., de la Torre L., et al. Anti-HLA antibodies in heart transplantation. Transpl Immunol 12 (2004) 177-183